Skip to main content
NUTRITION 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session: Vitamins and Minerals (Poster Theater Flash Session 13)

(PTFS13-01-24) The Effect of Zinc Supplementation on Endocrine Parameters and Hormonal Profiles in Women Diagnosed With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Monday, July 1, 2024
10:00 AM – 10:04 AM CT
Location:  W185A-C
Objectives: This study aim to assess the impact of zinc supplementation on hormonal and metabolic factors in women diagnosed with Polycystic Ovary Syndrome (PCOS).

Methods: Adhering to PRISMA guidelines, we conducted a thorough search for randomized controlled trials that examined the impact of zinc supplementation in women with PCOS. Our focus was on various outcomes, such as fasting plasma glucose, glutathione, interleukin-6, magnesium, malondialdehyde (MDA), nitric oxide (NO), Quantitative Insulin Sensitivity Check Index (QUICKI), serum insulin levels, Total Antioxidant Capacity (TAC), and High-Density Lipoprotein (HDL) cholesterol. The study conducted meta-analyses using fixed-effects models to determine standardized mean differences (SMDs) and 95% confidence intervals (CI). The Cochrane tool was used to assess the risk of bias.

Results: A total of eight trials involving 586 subjects showed that zinc supplementation led to significant improvements in fasting plasma glucose levels (standardized mean difference [SMD]: -0.42, 95% confidence interval [CI]: -0.80 to -0.05). However, there were no significant changes in glutathione levels (SMD: -0.05, 95% CI: -0.35 to 0.26). The indicators of insulin sensitivity, HOMA-IR (SMD: -1.32, 95% CI: -1.77 to -0.88) and QUICKI (SMD: 0.64, 95% CI: 0.25 to 1.03), showed improvement. Additionally, there were reductions in hs-CRP (SMD: -0.69, 95% CI: -1.02 to -0.37) and MDA (SMD: -1.04, 95% CI: -1.39 to -0.69). Nevertheless, the results showed that interleukin-6 (SMD: 2.35, 95% CI: 1.68 to 3.02) and magnesium levels (SMD: 0.66, 95% CI: 0.40 to 0.92) were more favorable towards the placebo, suggesting the presence of negative effects. There was no improvement in NO levels (SMD: -0.38, 95% CI: -0.70 to -0.06), as well as serum insulin (SMD: -0.43, 95% CI: -0.73 to -0.13) and HDL cholesterol (SMD: -0.81, 95% CI: -1.20 to -0.42). However, TAC did not provide any benefits (SMD: 1.25, 95% CI: 0.80 to 1.69).

Conclusions: The results indicate that zinc supplementation has a considerable positive effect on various important biochemical and inflammatory indicators in PCOS. This highlights the potential usefulness of zinc as an additional therapy approach. The variety of results highlights the intricate nature of PCOS and the need for customized treatment options.

Funding Sources: This research/abstract received no external funding.